Beta Bionics Inc. (BBNX)
Beta Bionics Statistics
Share Statistics
Beta Bionics has 43.35M shares outstanding. The number of shares has increased by null% in one year.
| Shares Outstanding | 43.35M |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | n/a |
| Owned by Institutions (%) | n/a |
| Shares Floating | - |
| Failed to Deliver (FTD) Shares | 81.78K |
| FTD / Avg. Volume | 12.83% |
Short Selling Information
The latest short interest is 1.18M, so 2.73% of the outstanding shares have been sold short.
| Short Interest | 1.18M |
| Short % of Shares Out | 2.73% |
| Short % of Float | 0% |
| Short Ratio (days to cover) | 4.74 |
Valuation Ratios
The PE ratio is -2.75 and the forward PE ratio is null. Beta Bionics's PEG ratio is -0.79.
| PE Ratio | -2.75 |
| Forward PE | n/a |
| PS Ratio | 2.31 |
| Forward PS | null |
| PB Ratio | 1.98 |
| P/FCF Ratio | -2.91 |
| PEG Ratio | -0.79 |
Enterprise Valuation
Currently the Enterprise Value (EV) is not available for Beta Bionics.
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 6.29, with a Debt / Equity ratio of 0.1.
| Current Ratio | 6.29 |
| Quick Ratio | 5.66 |
| Debt / Equity | 0.1 |
| Debt / EBITDA | -0.16 |
| Debt / FCF | -0.14 |
| Interest Coverage | 0 |
Financial Efficiency
Return on Equity is n/a and Return on Invested Capital is n/a.
| Return on Equity | n/a |
| Return on Assets | n/a |
| Return on Invested Capital | n/a |
| Revenue Per Employee | $223.79K |
| Profits Per Employee | $-188.16K |
| Employee Count | 291 |
| Asset Turnover | 0.44 |
| Inventory Turnover | 2.19 |
Taxes
| Income Tax | 0 |
| Effective Tax Rate | 0% |
Stock Price Statistics
The stock price has increased by null% in the last 52 weeks. The beta is 0, so Beta Bionics's price volatility has been lower than the market average.
| Beta | 0 |
| 52-Week Price Change | null% |
| 50-Day Moving Average | 16.87 |
| 200-Day Moving Average | null |
| Relative Strength Index (RSI) | 35.73 |
| Average Volume (20 Days) | 637.47K |
Income Statement
In the last 12 months, Beta Bionics had revenue of 65.12M and earned -54.76M in profits. Earnings per share was -8.6.
| Revenue | 65.12M |
| Gross Profit | 35.89M |
| Operating Income | -45.25M |
| Net Income | -54.76M |
| EBITDA | -44.1M |
| EBIT | -45.25M |
| Earnings Per Share (EPS) | -8.6 |
Balance Sheet
The company has 30.43M in cash and 7.25M in debt, giving a net cash position of 23.18M.
| Cash & Cash Equivalents | 30.43M |
| Total Debt | 7.25M |
| Net Cash | 23.18M |
| Retained Earnings | -296.74M |
| Total Assets | - |
| Working Capital | - |
Cash Flow
In the last 12 months, operating cash flow was -48.27M and capital expenditures -3.4M, giving a free cash flow of -51.67M.
| Operating Cash Flow | -48.27M |
| Capital Expenditures | -3.4M |
| Free Cash Flow | -51.67M |
| FCF Per Share | -8.12 |
Margins
Gross margin is 55.11%, with operating and profit margins of -69.48% and -84.08%.
| Gross Margin | 55.11% |
| Operating Margin | -69.48% |
| Pretax Margin | -84.08% |
| Profit Margin | -84.08% |
| EBITDA Margin | -67.72% |
| EBIT Margin | -69.48% |
| FCF Margin | -79.34% |
Dividends & Yields
BBNX does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | n/a |
| FCF Yield | n/a |
Analyst Forecast
The average price target for BBNX is $27, which is 157.4% higher than the current price. The consensus rating is "Buy".
| Price Target | $27 |
| Price Target Difference | 157.4% |
| Analyst Consensus | Buy |
| Analyst Count | 6 |
Scores
| Altman Z-Score | null |
| Piotroski F-Score | null |